Jumlah Kunjungan, Profil Pengobatan, dan HRQoL Pasien Rawat Jalan DM Tipe 2 pada Era JKN
Kata Kunci:
JKN, jumlah kunjungan, jumlah obat, HRQoL, DM tipe 2Abstrak
Public insurance has transformed since 1st January 2014 from Asuransi Kesehatan (ASKES) to Jaminan Kesehatan Nasional (JKN). There is different payment method between ASKES and JKN. ASKES uses fee for services (FFS) method and JKN uses INA-CBG’s method. The aims of this research were to determine the impact of implementation of JKN to number of hospital visit, treatment profile, and HRQoL among type 2 DM outpatients at one of Hospital type B in Jakarta. The research was conducted by time series longitudinal. Total samples were 103 patients. Among of them were 36(35%) male and 67(65%) female. There were 98% patients with age of more than 45 years old. 95(92%) patients were diagnosed DM without complication and 8(8%) were DM with complication. After implementation of JKN, there were decreasing number of hospital visit and number of drug perpatient among type 2 DM outpatients without and with complication. We also founded that the percentage of non DM drugs was higher than DM drugs. Statistically, number of DM and non DM drugs was not difference significant between before and after JKN (P>0.05). Score average of HRQoL in era of JKN was more than 80. This score showed that patients had good quality of life. Related to statistical analysis, quality of life was difference based on gender and age. In conclusion, there were different number of drugs and treatment profile after JKN implemented and patients performed good quality of life in era of JKN.
Referensi
Unduhan
Diterbitkan
Terbitan
Bagian
Lisensi
Licencing
All articles in Jurnal Ilmu Kefarmasian Indonesia are an open-access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which permits unrestricted non-commercial used, distribution and reproduction in any medium.
This licence applies to Author(s) and Public Reader means that the users mays :
- SHARE:
copy and redistribute the article in any medium or format - ADAPT:
remix, transform, and build upon the article (eg.: to produce a new research work and, possibly, a new publication) - ALIKE:
If you remix, transform, or build upon the article, you must distribute your contributions under the same license as the original. - NO ADDITIONAL RESTRICTIONS:
You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
It does however mean that when you use it you must:
- ATTRIBUTION: You must give appropriate credit to both the Author(s) and the journal, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
You may not:
- NONCOMMERCIAL: You may not use the article for commercial purposes.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

















